NSE filing, NSE: SHADOWFAX. Summary written from the filing by ALFA Finder's alert engine.
Shadowfax Technologies Ltd: key numbers
- Share price
- ₹294.00
- Market cap
- ₹17,258 Cr
- Revenue (annual)
- ₹4,202 Cr
- Net profit (annual)
- ₹111.7 Cr
- P/E (TTM)
- 77.0×Sector 29.6×
- Promoter holding
- 16.46%-0.05% QoQ
- FII holding
- 16.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shadowfax Technologies Ltd
All →Shadowfax Technologies Earnings Call Transcript: Key Takeaways
Shadowfax hit record ₹1,538 Cr revenue and 5% EBITDA margin, signaling strong transition toward profitability.
Shadowfax Technologies Other Announcement
Shadowfax submitted CARE Ratings' monitoring agency report on IPO proceeds for the quarter ended September 30, 2026. The report shows no deviation from the offer objects.
Shadowfax Technologies Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹1,538 Cr (+56.6% YoY), PAT ₹68 Cr (4.4% margin), Adj. EBITDA ₹77 Cr (5.0% margin); speed-led share gains across Express, Hyperlocal and Prime D2C.
Shadowfax Technologies Results Update
Shadowfax reported Q2 FY27 revenue of ₹1,538 Cr, up 56.6% YoY, with PAT at ₹68 Cr. Sixth consecutive 55%+ growth quarter, Adj. EBITDA margin at 5.0%.
Shadowfax Technologies Q2 FY27 Results: Net Profit ₹68 Cr, Up 423.1% YoY
Shadowfax Technologies Ltd reported revenue from operations of ₹1,538 Cr (+56.6% YoY) and net profit of ₹68 Cr (+423.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹68 Cr · +423.1% YoY
Shadowfax Technologies Board Meeting Date
Shadowfax Technologies will hold a board meeting on 29 October 2026 to approve September 2026 quarter results. An earnings call follows the same day at 5 p.m.
Other employee stock options announcements
All →Borosil Employee Stock Options
Borosil granted 7,23,200 employee stock options at Rs 192.8 each under its 2020 scheme. Options vest in three tranches over three years.
- Execution
- Vesting over 3 years from grant date
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr
Coforge Employee Stock Options
Coforge allotted 24,242 equity shares under its ESOP (2005) scheme on 29 October 2026. Paid-up capital rises to 44,30,62,864 equity shares.
Greenply Industries Employee Stock Options
Greenply Industries allotted 500 equity shares under its ESOP 2020 scheme on 29 October 2026. The allotment lifts paid-up capital to Rs.12,49,02,545.
Firstsource Solutions Employee Stock Options
Firstsource's Nomination and Remuneration Committee approved a grant of 587,750 stock options to eligible employees. The grant falls under its 2019 Employee Stock Option Plan.
Vedanta Power Employee Stock Options
Vedanta Power granted 78,11,356 ESOP stock options under VPL ESOP 2026 to eligible employees including KMP. Options vest over 36 months at an exercise price of Rs 10 per share.
- Execution
- 36 months vesting from grant date; exercisable within 8 months of vesting